Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims in this application:

1. (previously presented) A stabilized drug delivery system for proton pump inhibitors comprising rabeprazole sodium, mannitol, an alkaline compound, and water for injection, wherein the molar ratio of rabeprazole sodium to the alkaline compound is about 1:0.359, and the pH of the system is 9-11.

2-6. (cancelled)

7. (currently amended) The drug delivery system as claimed in claim ~~5~~ 1, wherein said alkaline compound is sodium hydroxide.

8. (cancelled)

9. (previously presented) The drug delivery system as claimed in claim 1, wherein said rabeprazole sodium is present in the range of 8% to 77% by weight of the total composition.

10. (previously presented) The drug delivery system as claimed in claim 1, wherein said mannitol is present in the range of 19% to 88% by weight of the total composition.

11. (cancelled)

12. (previously presented) The drug delivery system for proton pump inhibitor prepared by process as claimed in claim 18.

13-15. (cancelled)

16. (previously presented) The drug delivery system as claimed in claim 9, wherein said rabeprazole sodium compound is present in the range of 19 - 62% by weight of the total composition.

17. (previously presented) The drug delivery system as claimed in claim 10, wherein said mannitol is present in the range of 30% - 88% by weight of the total composition.

18. (previously presented) A process for preparation of the said drug delivery system comprising the steps of

(a) dissolving sodium hydroxide in water for injection to adjust the pH above 12.0 using an alkaline compound to form a solution;

(b) adding mannitol and rabeprazole sodium to said solution while maintaining the pH of said solution, wherein the molar ratio of rabeprazole sodium to the alkaline compound is about 1:0.359;

(c) making up the volume with water for injection;

(d) filtering the said solution aseptically through 0.22μ filter paper;

(e) filling the said filtered solution in previously sterilized 10ml vials;

(f) maintaining the temperature of the injectable solution at 10°C±2°C throughout the process;

(g) loading the vials into lyophilizer after partial bunging; and

(f) lyophilizing the solution to obtain a powder form the drug delivery system which is reconstitutable in a parenterally acceptable solvent to form an injectable solution.